Tyrosine phosphatase Shp2 mediates the estrogen biological action in breast cancer via interaction with the estrogen extranuclear receptor

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Li, Jun ^a   Kang, Yujia ^a   Wei, Longgang ^a   Liu, Wenjie ^a   Tian, Yingpu ^a   Chen, Baozhen ^b   Lin, Xiandong ^b   Li, Yang ^a   Feng, Gen Sheng ^c   Lu, Zhongxian ^a  

^a XIAMEN UNIVERSITY   (China)

^b FUJIAN PROVINCIAL TUMOR HOSPITAL   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; DIMETHYLBENZ[A]ANTHRACENE; DNA; ESTROGEN RECEPTOR; PROTEIN KINASE; PROTEIN TYROSINE PHOSPHATASE; SMALL INTERFERING RNA; SOMATOMEDIN; TREFOIL PEPTIDE; TYROSINE PHOSPHATASE SHP2; UNCLASSIFIED DRUG; BENZENESULFONIC ACID DERIVATIVE; ESTRADIOL; ESTROGEN; HYDRAZONE DERIVATIVE; PHENYLHYDRAZONOPYRAZOLONE SULFONATE 1; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CARCINOGENESIS; CELL GROWTH; CONTROLLED STUDY; DNA SYNTHESIS; FEMALE; GENETIC TRANSCRIPTION; MAMMARY GLAND; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECTS; EXPERIMENTAL MAMMARY NEOPLASM; HUMAN; METABOLISM; MOUSE; PHOSPHORYLATION; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; BENZENESULFONATES; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; HYDRAZONES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN;

EID: 84904598409     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102847     Document Type: Article

References (55)

1. Irsik DL, Carmines PK, Lane PH (2013) Classical estrogen receptors and ERalpha splice variants in the mouse. PLoS One 8:e70926.
2. Levin ER (2009) Plasma membrane estrogen receptors. Trends Endocrinol Metab 20:477-482.
3. Bolli A, Marino M (2011) Current and future development of estrogen receptor ligands: applications in estrogen-related cancers. Recent Pat Endocr Metab Immune Drug Discov 5:210-229.
4. Cortez V, Mann M, Brann DW, Vadlamudi RK (2010) Extranuclear signaling by estrogen: role in breast cancer progression and metastasis. Minerva Ginecol 62:573-583.
5. Chakravarty D, Nair SS, Santhamma B, Nair BC, Wang L, et al (2010) Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells. Cancer Res 70:4092-4101.
6. Williams C, Lin CY (2013) Oestrogen receptors in breast cancer: basic mechanisms and clinical implications. Ecancermedicalscience 7:370.
7. Acconcia F, Marino M (2011) The Effects of 17beta-estradiol in Cancer are Mediated by Estrogen Receptor Signaling at the Plasma Membrane. Front Physiol 2:30.
8. Lappano R, De Marco P, De Francesco EM, Chimento A, Pezzi V, et al (2013) Cross-talk between GPER and growth factor signaling. J Steroid Biochem Mol Biol 137:50-56.
9. Thomas P, Pang Y, Filardo EJ, Dong J (2005) Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146:624-632. (Pubitemid 40129818)
10. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, et al (2002) Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 16:116-127. (Pubitemid 34044502)
11. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, et al (2001) PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. Embo J 20:6050-6059. (Pubitemid 33049280)
12. Driggers PH, Segars JH (2002) Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol Metab 13:422-427.
13. Boyan BD, Sylvia VL, Frambach T, Lohmann CH, Dietl J, et al (2003) Estrogen-dependent rapid activation of protein kinase C in estrogen receptor-positive MCF-7 breast cancer cells and estrogen receptor-negative HCC38 cells is membrane-mediated and inhibited by tamoxifen. Endocrinology 144:1812-1824. (Pubitemid 36543319)
14. Zivadinovic D, Watson CS (2005) Membrane estrogen receptor-alpha levels predict estrogen-induced ERK1/2 activation in MCF-7 cells. Breast Cancer Res 7:R130-144.
15. Fu XD, Cui YH, Lin GP, Wang TH (2007) Non-genomic effects of 17beta-estradiol in activation of the ERK1/ERK2 pathway induces cell proliferation through upregulation of cyclin D1 expression in bovine artery endothelial cells. Gynecol Endocrinol 23:131-137.
16. Marino M, Acconcia F, Trentalance A (2003) Biphasic estradiol-induced AKT phosphorylation is modulated by PTEN via MAP kinase in HepG2 cells. Mol Biol Cell 14:2583-2591. (Pubitemid 36724344)
17. Dos Santos EG, Dieudonne MN, Pecquery R, Le Moal V, Giudicelli Y, et al (2002) Rapid nongenomic E2 effects on p42/p44 MAPK, activator protein-1, and cAMP response element binding protein in rat white adipocytes. Endocrinology 143:930-940. (Pubitemid 34164041)
18. Haynes MP, Li L, Sinha D, Russell KS, Hisamoto K, et al (2003) Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. J Biol Chem 278:2118-2123. (Pubitemid 36801275)
19. Neel BG, Gu H, Pao L (2003) The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 28:284-293. (Pubitemid 36776291)
20. Feng GS (1999) Shp-2 tyrosine phosphatase: signaling one cell or many. Exp Cell Res 253:47-54.
21. Tartaglia M, Gelb BD (2005) Germ-line and somatic PTPN11 mutations in human disease. Eur J Med Genet 48:81-96. (Pubitemid 40692207)
22. Feng GS (2006) Shp2 as a therapeutic target for leptin resistance and obesity. Expert Opin Ther Targets 10:135-142.
23. Chan RJ, Feng GS (2007) PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 109:862-867. (Pubitemid 46220628)
24. Mohi MG, Neel BG (2007) The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev 17:23-30. (Pubitemid 46131442)
25. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, et al (2003) Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 34:148-150. (Pubitemid 36666923)
26. Lazzara MJ, Lane K, Chan R, Jasper PJ, Yaffe MB, et al (2010) Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations. Cancer Res 70:3843-3850.
27. Furcht CM, Munoz Rojas AR, Nihalani D, Lazzara MJ (2012) Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations. Oncogene.
28. Martinelli S, Carta C, Flex E, Binni F, Cordisco EL, et al (2006) Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors. Cancer Genet Cytogenet 166:124-129.
29. Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, et al (2004) Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 64:8816-8820. (Pubitemid 39665483)
30. Miyamoto D, Miyamoto M, Takahashi A, Yomogita Y, Higashi H, et al (2008) Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors. Oncogene 27:3508-3515. (Pubitemid 351793798)
31. Navis AC, van den Eijnden M, Schepens JT, Hooft van Huijsduijnen R, Wesseling P, et al (2010) Protein tyrosine phosphatases in glioma biology. Acta Neuropathol 119:157-175.
32. Tebbutt NC, Giraud AS, Inglese M, Jenkins B, Waring P, et al (2002) Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 8:1089-1097. (Pubitemid 35175963)
33. Hou HA, Chou WC, Lin LI, Chen CY, Tang JL, et al (2007) Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD. Leukemia.
34. Bard-Chapeau EA, Li S, Ding J, Zhang SS, Zhu HH, et al (2011) Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 19:629-639.
35. Bentires-Alj M, Gil SG, Chan R, Wang ZC, Wang Y, et al (2006) A role for the scaffolding adapter GAB2 in breast cancer. Nat Med 12:114-121. (Pubitemid 43050085)
36. Zhou X, Agazie YM (2009) Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation. J Biol Chem 284:12226-12234.
37. Ke Y, Wu D, Princen F, Nguyen T, Pang Y, et al (2007) Role of Gab2 in mammary tumorigenesis and metastasis. Oncogene 26:4951-4960. (Pubitemid 47172654)
38. Aceto N, Sausgruber N, Brinkhaus H, Gaidatzis D, Martiny-Baron G, et al (2012) Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med 18:529-537.
39. Zhou X, Coad J, Ducatman B, Agazie YM (2008) SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis. Histopathology 53:389-402.
40. Daly RJ, Gu H, Parmar J, Malaney S, Lyons RJ, et al (2002) The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer. Oncogene 21:5175-5181.
41. Hellmuth K, Grosskopf S, Lum CT, Wurtele M, Roder N, et al (2008) Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. Proc Natl Acad Sci U S A 105:7275-7280. (Pubitemid 351754468)
42. Costa I, Solanas M, Escrich E (2002) Histopathologic characterization of mammary neoplastic lesions induced with 7,12 dimethylbenz(alpha)anthracene in the rat: a comparative analysis with human breast tumors. Arch Pathol Lab Med 126:915-927.
43. Labrie F, Li S, Labrie C, Levesque C, Merand Y (1995) Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Breast Cancer Res Treat 33:237-244.
44. Lee H, Bai W (2002) Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol Cell Biol 22:5835-5845. (Pubitemid 34815832)
45. Murphy LC, Seekallu SV, Watson PH (2011) Clinical significance of estrogen receptor phosphorylation. Endocr Relat Cancer 18:R1-14.
46. Zhou W, Slingerland JM (2014) Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nat Rev Cancer 14:26-38.
47. He Z, Zhang SS, Meng Q, Li S, Zhu HH, et al (2012) Shp2 controls female body weight and energy balance by integrating leptin and estrogen signals. Mol Cell Biol 32:1867-1878.
48. Harari D, Yarden Y (2000) Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19:6102-6114. (Pubitemid 32059460)
49. Ariazi EA, Kraus RJ, Farrell ML, Jordan VC, Mertz JE (2007) Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway. Mol Cancer Res 5:71-85.
50. Ascenzi P, Bocedi A, Marino M (2006) Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med 27:299-402. (Pubitemid 44255847)
51. Fritzsche FR, Dahl E, Pahl S, Burkhardt M, Luo J, et al (2006) Prognostic relevance of AGR2 expression in breast cancer. Clin Cancer Res 12:1728-1734.
52. Sum EY, Segara D, Duscio B, Bath ML, Field AS, et al (2005) Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer. Proc Natl Acad Sci U S A 102:7659-7664. (Pubitemid 40741027)
53. Wu D, Pang Y, Ke Y, Yu J, He Z, et al (2009) A conserved mechanism for control of human and mouse embryonic stem cell pluripotency and differentiation by shp2 tyrosine phosphatase. PLoS One 4:e4914.
54. Lu Z, Lam KS, Wang N, Xu X, Cortes M, et al (2006) LMO4 can interact with Smad proteins and modulate transforming growth factor-beta signaling in epithelial cells. Oncogene 25:2920-2930. (Pubitemid 43739242)
55. Qu CK (2002) Role of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response. Biochim Biophys Acta 1592:297-301.